Effect of Gender Affirming Hormone Therapy on Glucose Metabolism
Lay Description
The study will test:
- whether estrogen treatment in transwomen is associated with improved insulin sensitivity and beta cell function
- whether testosterone treatment in transmen is associated with worsening insulin sensitivity and beta cell function
- whether estrogen therapy leads to enhanced immune response in older transwormen
Category
- Other
- IRB Number
- 20190415HU
- NCT Number
- NCT04515472
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Healthy volunteers: healthy male or female
- MTF transgender
- FTM transgender
- Non-diabetic (A1c<6.5%), fasting glucose <126mg/dl and OGTT after 2 hr <200mg/dl)
- Stable hormone treatment (estrogen or testosterone) for at least 6 months
Exclusion Criteria
- History of or newly diagnosed diabetes mellitus
- For healthy volunteers, not current treatment with estrogen or testosterone
- For FTM transgender, no recent cardiovascular event: acute coronary syndrome (ACS), stroke (CVA)
- For MTF and FTM transgender, less than 6 months of stable hormone treatment
- Anemia with hemoglobin (Hb) <11.0 hematocrit (Hto) < 34 and Glomerular Filtration rate (GFR) <30
Study Design
Arm Groups
Study Contact
Andrea Hansis-Diarte
210-567-3208
hansisdiarte@uthscsa.edu
Principal Investigator
Devjit Tripathy